Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours  participating in the EORTC STBSG 62024 adjuvant imatinib study

EORTC (European Organisation of Research and Treatment of Cancer) 62024 is a phase III  randomised trial evaluating adjuvant imatinib in patients with gastrointestinal stromal tumours (GISTs) and no evidence of residual disease after surgery in 908 patients from 11 countries participated. As surgical treatment aspects (tumour rupture and incomplete resection) contribute to the risk o f recurrence, the data of primary surgery were reviewed.

Source: European Journal of Cancer - August 30, 2019 Category: Cancer & Oncology Authors: Peter Hohenberger, Sylvie Bonvalot, Frits van Coevorden, Pjotr Rutkowski, Eberhard Stoeckle, Christine Olungu, Saskia Litiere, Eva Wardelmann, Alessandro Gronchi, Paolo Casali Tags: Original Research Source Type: research